NCT05896605View on ClinicalTrials.gov

Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

April 1, 2023

Conditions
NMO Spectrum DisorderAzathioprine Adverse Reaction
Interventions
DRUG

Azathioprine

Before medication, TPMT activity was normal, and AZA was started at small doses and added every two weeks after no AEs, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid.

Trial Locations (1)

530021

Qingmeng Huang, Nanning

All Listed Sponsors
lead

First Affiliated Hospital of Guangxi Medical University

OTHER

NCT05896605 - Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder | Biotech Hunter | Biotech Hunter